Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
作者： Udo Vanhoefer , Andreas Harstrick , Wolf Achterrath , Shousong Cao , Siegfried Seeber
DOI: 10.1200/JCO.2001.19.5.1501
关键词: Fluorouracil 、 Clinical trial 、 Surgery 、 Chemotherapy 、 Topoisomerase 、 Oncology 、 Colorectal cancer 、 Irinotecan 、 Rectum 、 Regimen 、 Medicine 、 Internal medicine
摘要: … The therapeutic value of irinotecan in the first-line … of irinotecan and FU/LV with FU/LV alone. Both trials demonstrated significant superior efficacy for the combination of irinotecan and …
sci-hub.se 参考文章(145)
S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, C. Focan, P. Chollet, J.F. Llory, Y. Letourneau, B. Coudert, F. Bertheaut-Cvitkovic, D. Larregain-Fournier, A. Le Rol, S. Walter, R. Adam, J.L. Misset, F. Lévi, Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 18, pp. 136- 136 ,(2000) , 10.1200/JCO.2000.18.1.136
M.L. Rothenberg, Topoisomerase I inhibitors: Review and update Annals of Oncology. ,vol. 8, pp. 837- 855 ,(1997) , 10.1023/A:1008270717294
S. Negoro, M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudoh, H. Niitani, T. Taguchi, Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 83, pp. 1164- 1168 ,(1991) , 10.1093/JNCI/83.16.1164
Tsuyoshi Yokoi, Michiyuki Kato, Tetsuya Kamataki, Takehiro Hagiwara, Masaaki Hirohashi, Kiyoshi Takasuna, Eiichi Nagai, Mamoru Nomura, Involvement of β-Glucuronidase in Intestinal Microflora in the Intestinal Toxicity of the Antitumor Camptothecin Derivative Irinotecan Hydrochloride (CPT-11) in Rats Cancer Research. ,vol. 56, pp. 3752- 3757 ,(1996)
M L Rothenberg, J G Kuhn, H A Burris, J Nelson, J R Eckardt, M Tristan-Morales, S G Hilsenbeck, G R Weiss, L S Smith, G I Rodriguez, Phase I and pharmacokinetic trial of weekly CPT-11 Journal of Clinical Oncology. ,vol. 11, pp. 2194- 2204 ,(1993) , 10.1200/JCO.1993.11.11.2194
G. Catimel, G.G. Chabot, J.P. Guastalla, A. Dumortier, C. Cote, C. Engel, A. Gouyette, A. Mathieu-Boué, M. Mahjoubi, M. Clavel, Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors Annals of Oncology. ,vol. 6, pp. 133- 140 ,(1995) , 10.1093/OXFORDJOURNALS.ANNONC.A059108
P Canal, C Gay, A Dezeuze, J Y Douillard, R Bugat, R Brunet, A Adenis, P Herait, F Lokiec, A Mathieu-Boue, Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology. ,vol. 14, pp. 2688- 2695 ,(1996) , 10.1200/JCO.1996.14.10.2688
S Wadler, A B Benson, C Engelking, R Catalano, M Field, S M Kornblau, E Mitchell, J Rubin, P Trotta, E Vokes, Recommended guidelines for the treatment of chemotherapy-induced diarrhea. Journal of Clinical Oncology. ,vol. 16, pp. 3169- 3178 ,(1998) , 10.1200/JCO.1998.16.9.3169
G.J. Creemers, J. Wanders, T. Gamucci, S. Vallentin, L.Y. Dirix, P. Schöffski, I. Hudson, J. Verweij, Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group Annals of Oncology. ,vol. 6, pp. 844- 846 ,(1995) , 10.1093/OXFORDJOURNALS.ANNONC.A059328
G.G. Chabot, D. Abigerges, G. Catimel, S. Culine, M. de Forni, J.-M. Extra, M. Mahjoubi, P. Hérait, J.-P. Armand, R. Bugat, M. Clavel, M.E. Marty, Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials* Annals of Oncology. ,vol. 6, pp. 141- 151 ,(1995) , 10.1093/OXFORDJOURNALS.ANNONC.A059109